Prescription painkillers and heroin addiction is plaguing the state of Ohio, as well as the rest of the nation. However, limiting office-based treatment using buprenorphine products is not the solution.
The OPPA had an opportunity recently to share its concerns with Chairman Ryan Smith and members of the House Health & Aging Subcommittee on Opiate Addiction Treatment and Reform:
OPPA Testimony on HB 378 - Related to Office-Based Opioid Treatment Limits
Related Information:
OPPA opposes Medical Board draft rules on office-based opiate treatment using buprenorphine